Related Experiment Video
Updated: Jun 15, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
Everolimus
1Center for Childhood Cancer, The Research Institute, Nationwide Children's Hospital, Columbus, Ohio 43205, USA. Peter.Houghton@nationwidechildrens.org
Abstract:
Everolimus, an orally administered rapamycin analog, has recently been approved by the U.S. Food and Drug Administration for treatment of renal cell carcinoma (RCC) refractory to inhibitors of vascular endothelial growth factor (VEGF) receptor signaling. Everolimus significantly increased progression-free survival (median PFS for the everolimus treated group was 4.0 months versus 1.9 months for the placebo group), although tumor regressions were observed only infrequently. Although the target for everolimus, [the serine-threonine kinase mammalian target of rapamycin (mTOR)] is well established, the mechanism by which this agent retards tumor growth is not well defined. Further, biomarkers that predict tumor sensitivity are still elusive. The mechanism of action, preclinical antitumor activity, and clinical activity of everolimus against RCC are reviewed.
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Renal Drug Excretion: Tubular Secretion
Bioequivalence studies: Biowaivers
Drug Elimination by Renal Route: Tubular Secretion
Drug Elimination by Renal Route: Tubular Reabsorption
